<DOC>
	<DOC>NCT00207103</DOC>
	<brief_summary>This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.</brief_summary>
	<brief_title>MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors No tumor spread to the brain Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.) Available tumor tissue sample from prior surgery 46 weeks since prior therapy and recovered from prior therapy Men and women, ages 18 and above Women must not be pregnant or breastfeeding Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer Measurable disease on scans (at least one)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Advanced metastatic or solid tumors</keyword>
</DOC>